Mistletoe and cancer: Controversies and perspectives☆☆☆
Abstract
Extracts and preparations from the tree parasitic plant mistletoe (Viscum album L.) have been used in the treatment of cancer for decades. Numerous preclinical and in vitro studies have reported immunostimulatory, cytotoxic, and proapoptotic effects. Translation of these effects into clinical response continues to pose a problem. While a number of clinical studies have found improvement in quality of life (QOL), data on the efficacy of mistletoe to prolong survival are conflicting and of variable quality. Clinical trial data regarding the toxicity and pharmacokinetics of mistletoe components with known in vitro or preclinical activity are lacking. Mistletoe is a widely used form of complementary and alternative medicine (CAM) for cancer treatment, and research into its use poses the challenges of translation of preclinical data into demonstrable clinical efficacy and investigating CAM approaches as a component of complex cancer treatment systems. Semin Oncol 29:589-594. This is a US government work. There are no restrictions on its use.
To access this article, please choose from the options below
☆ Address reprint requests to Patrick J. Mansky, MD, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health, 8 West Dr, Quarters 15-B1, MSC 2669, Bethesda, MD 20892.
☆☆ This is a US government work. There are no restrictions on its use.
PII: S0093-7754(02)50322-5
doi:10.1053/sonc.2002.50006
© 2002 Published by Elsevier Inc.
